Pharmaceuticals, Biotechnology and Life Sciences
US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First
Patient Showing Positive Initial Treatment
The trial, for treatment of patients suffering from AcuteMyeloid Leukemia (AML), is being conducted at the Institute ofHematology and Blood Transfusion (ÚHKT) in Prague, Czech Republic.
Rexgenero presented an update on its two Phase III SALAMANDER trials beingconducted across Europe for its lead development programme REX-001 totreat CLI in patients with diabetes.
Punit Upadhyaya, Ph.D., SeniorScientist at Bicycle, will present at the 6th Annual PeptidesCongress in London.
Ipsen Q1 2019 sales growth of 17.0% as reported, or 15.8%1at constant exchange rates and consolidation scope.
Dr. Mark Erlander, Chief Scientific Officer of Trovagene. “We believe the positive results of our preclinical study provides the scientific rationale for clinical investigation of this combination regimen and may lead to a new treatment option for these patients.”
Pfizer and Eli lilly have announced top-line results from a Phase 3 study evaluating tanezumab 2.5mg and 5 mg.
Winther trial shows RNA profiling togetherwith DNA testing matches more patients with advanced cancer topersonalized therapies than DNA profiling for tumor mutations alone.
Daniel Soland has been appointed to Kalvista Board of Directors .
The global anticoagulants reversal drugs market expected to expand at aCAGR of 15.3% from 2018 to 2026, owing to the approval of blockbusterdrugs in recent years and strong pipeline driving the market.